|
1
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK:
Diagnosisstaging, and management of hepatocellular carcinoma: 2018
Practice guidance by the american association for the study of
liver diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kluger MD, Salceda JA, Laurent A, Tayar C,
Duvoux C, Decaens T, Luciani A, Van Nhieu JT, Azoulay D and Cherqui
D: Liver resection for hepatocellular carcinoma in 313 western
patients: Tumor biology and underlying liver rather than tumor size
drive prognosis. J Hepatol. 62:1131–1140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao L, Wu X, Li T, Luo J and Dong D:
ctcRbase: The gene expression database of circulating tumor cells
and microemboli. Database (Oxford). 2020:baaa0202020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alix-Panabières C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Plaks V, Koopman CD and Werb Z: Cancer.
Circulating tumor cells. Science. 341:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Szczerba BM, Castro-Giner F, Vetter M,
Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R,
Singer J, et al: Neutrophils escort circulating tumour cells to
enable cell cycle progression. Nature. 566:553–557. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aceto N, Bardia A, Miyamoto DT, Donaldson
MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al:
Circulating tumor cell clusters are oligoclonal precursors of
breast cancer metastasis. Cell. 158:1110–1122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lo HC, Xu Z, Kim IS, Pingel B, Aguirre S,
Kodali S, Liu J, Zhang W, Muscarella AM, Hein SM, et al: Resistance
to natural killer cell immunosurveillance confers a selective
advantage to polyclonal metastasis. Nat Cancer. 1:709–722. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pereira-Veiga T, Schneegans S, Pantel K
and Wikman H: Circulating tumor cell-blood cell crosstalk: Biology
and clinical relevance. Cell Rep. 40:1112982022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J
Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hou JM, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye Q, Ling S, Zheng S and Xu X: Liquid
biopsy in hepatocellular carcinoma: Circulating tumor cells and
circulating tumor DNA. Mol Cancer. 18:1142019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Rubis G, Rajeev Krishnan S and Bebawy
M: Liquid biopsies in cancer diagnosis, monitoring, and prognosis.
Trends Pharmacol Sci. 40:172–186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu JJ, Xiao W, Dong SL, Liang HF, Zhang
ZW, Zhang BX, Huang ZY, Chen YF, Zhang WG, Luo HP, et al: Effect of
surgical liver resection on circulating tumor cells in patients
with hepatocellular carcinoma. BMC Cancer. 18:8352018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelley RK, Magbanua MJ, Butler TM,
Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM,
Hameed B, Wayne EM, et al: Circulating tumor cells in
hepatocellular carcinoma: A pilot study of detection, enumeration,
and next-generation sequencing in cases and controls. BMC Cancer.
15:2062015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu
SJ, Shi RY, Hu B, Zhou J and Fan J: Circulating stem cell-like
epithelial cell adhesion molecule-positive tumor cells indicate
poor prognosis of hepatocellular carcinoma after curative
resection. Hepatology. 57:1458–1468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y and Navin NE: Advances and
applications of single-cell sequencing technologies. Mol Cell.
58:598–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abouleila Y, Onidani K, Ali A, Shoji H,
Kawai T, Lim CT, Kumar V, Okaya S, Kato K, Hiyama E, et al: Live
single cell mass spectrometry reveals cancer-specific metabolic
profiles of circulating tumor cells. Cancer Sci. 110:697–706. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bhan I, Mosesso K, Goyal L, Philipp J,
Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, et
al: Detection and analysis of circulating epithelial cells in
liquid biopsies from patients with liver disease. Gastroenterology.
155:2016–2018.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tibshirani R: The lasso method for
variable selection in the Cox model. Stat Med. 16:385–395. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lossos IS, Czerwinski DK, Alizadeh AA,
Wechser MA, Tibshirani R, Botstein D and Levy R: Prediction of
survival in diffuse large-B-cell lymphoma based on the expression
of six genes. N Engl J Med. 350:1828–1837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gaujoux R and Seoighe C: A flexible R
package for nonnegative matrix factorization. BMC Bioinformatics.
11:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iasonos A, Schrag D, Raj GV and Panageas
KS: How to build and interpret a nomogram for cancer prognosis. J
Clin Oncol. 26:1364–1370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Finotello F, Mayer C, Plattner C,
Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W,
Wilflingseder D, et al: Molecular and pharmacological modulators of
the tumor immune contexture revealed by deconvolution of RNA-seq
data. Genome Med. 11:342019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Becht E, Giraldo NA, Lacroix L, Buttard B,
Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman
C, Fridman WH and de Reyniès A: Estimating the population abundance
of tissue-infiltrating immune and stromal cell populations using
gene expression. Genome Biol. 17:2182016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Aran D, Hu Z and Butte AJ: xCell:
Digitally portraying the tissue cellular heterogeneity landscape.
Genome Biol. 18:2202017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sturm G, Finotello F, Petitprez F, Zhang
JD, Baumbach J, Fridman WH, List M and Aneichyk T: Comprehensive
evaluation of transcriptome-based cell-type quantification methods
for immuno-oncology. Bioinformatics. 35:i436–i445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Racle J and Gfeller D: EPIC: A tool to
estimate the proportions of different cell types from bulk gene
expression data. Methods Mol Biol. 2120:233–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y,
Zhou R, Qiu W, Huang N, Sun L, et al: IOBR: Multi-omics
immuno-oncology biological research to decode tumor
microenvironment and signatures. Front Immunol. 12:6879752021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Malta TM, Sokolov A, Gentles AJ,
Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J,
Omberg L, Gevaert O, et al: Machine learning identifies stemness
features associated with oncogenic dedifferentiation. Cell.
173:338–354.e15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang W, Soares J, Greninger P, Edelman EJ,
Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et
al: Genomics of drug sensitivity in cancer (GDSC): A resource for
therapeutic biomarker discovery in cancer cells. Nucleic Acids Res.
41:D955–D961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ozga AJ, Chow MT and Luster AD: Chemokines
and the immune response to cancer. Immunity. 54:859–874. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vilgelm AE and Richmond A: Chemokines
modulate immune surveillance in tumorigenesis, metastasis, and
response to immunotherapy. Front Immunol. 10:3332019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ru B, Wong CN, Tong Y, Zhong JY, Zhong
SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An
integrated repository portal for tumor-immune system interactions.
Bioinformatics. 35:4200–4202. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Du Y, Ma Y, Zhu Q, Liu T, Jiao Y, Yuan P
and Wang X: An m6A-related prognostic biomarker associated with the
hepatocellular carcinoma immune microenvironment. Front Pharmacol.
12:7079302021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fu XW and Song CQ: Identification and
validation of pyroptosis-related gene signature to predict
prognosis and reveal immune infiltration in hepatocellular
carcinoma. Front Cell Dev Biol. 9:7480392021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guo DZ, Huang A, Wang YP, Cao Y, Fan J,
Yang XR and Zhou J: Development of an eight-gene prognostic model
for overall survival prediction in patients with hepatocellular
carcinoma. J Clin Transl Hepatol. 9:898–908. 2021.PubMed/NCBI
|
|
51
|
Lei D, Chen Y, Zhou Y, Hu G and Luo F: A
starvation-Based 9-mRNA signature correlates with prognosis in
patients with hepatocellular carcinoma. Front Oncol. 11:7167572021.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tian D, Yu Y, Zhang L, Sun J and Jiang W:
A five-gene-based prognostic signature for hepatocellular
carcinoma. Front Med (Lausanne). 8:6813882021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zheng S, Xie X, Guo X, Wu Y, Chen G, Chen
X, Wang M, Xue T and Zhang B: Identification of a
pyroptosis-related gene signature for predicting overall survival
and response to immunotherapy in hepatocellular carcinoma. Front
Genet. 12:7892962021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH,
Wang YY, Chen YY, Chen ZS, Ma L, Chen J, et al: Circulating tumor
cells undergoing EMT provide a metric for diagnosis and prognosis
of patients with hepatocellular carcinoma. Cancer Res.
78:4731–4744. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Schilling D, Todenhöfer T, Hennenlotter J,
Schwentner C, Fehm T and Stenzl A: Isolated, disseminated and
circulating tumour cells in prostate cancer. Nat Rev Urol.
9:448–463. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou H, Zhu L, Song J, Wang G, Li P, Li W,
Luo P, Sun X, Wu J, Liu Y, et al: Liquid biopsy at the frontier of
detection, prognosis and progression monitoring in colorectal
cancer. Mol Cancer. 21:862022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Diamantopoulou Z, Castro-Giner F, Schwab
FD, Foerster C, Saini M, Budinjas S, Strittmatter K, Krol I,
Seifert B, Heinzelmann-Schwarz V, et al: The metastatic spread of
breast cancer accelerates during sleep. Nature. 607:156–162. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Magri V, Marino L, Nicolazzo C, Gradilone
A, De Renzi G, De Meo M, Gandini O, Sabatini A, Santini D, Cortesi
E and Gazzaniga P: Prognostic role of circulating tumor cell
trajectories in metastatic colorectal cancer. Cells. 12:11722023.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xie J, Wang B, Luo W, Li C and Jia X:
Upregulation of KIF18B facilitates malignant phenotype of
esophageal squamous cell carcinoma by activating CDCA8/mTORC1
pathway. J Clin Lab Anal. 36:e246332022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xiang C, Sun WH, Ke Y, Yu X and Wang Y:
CDCA8 contributes to the development and progression of thyroid
cancer through regulating CDK1. J Cancer. 13:2322–2335. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ci C, Tang B, Lyu D, Liu W, Qiang D, Ji X,
Qiu X, Chen L and Ding W: Overexpression of CDCA8 promotes the
malignant progression of cutaneous melanoma and leads to poor
prognosis. Int J Mol Med. 43:404–412. 2019.PubMed/NCBI
|
|
62
|
Jeon T, Ko MJ, Seo YR, Jung SJ, Seo D,
Park SY, Park KU, Kim KS, Kim M, Seo JH, et al: Silencing CDCA8
suppresses hepatocellular carcinoma growth and stemness via
restoration of ATF3 tumor suppressor and inactivation of
AKT/β-catenin signaling. Cancers (Basel). 13:10552021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang Y, Martin TA and Jiang WG: HAVcR-1
expression in human colorectal cancer and its effects on colorectal
cancer cells in vitro. Anticancer Res. 33:207–214. 2013.PubMed/NCBI
|
|
64
|
Zheng X, Xu K, Chen L, Zhou Y and Jiang J:
Prognostic value of TIM-1 expression in human non-small-cell lung
cancer. J Transl Med. 17:1782019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cuadros T, Trilla E, Sarró E, Vilà MR,
Vilardell J, de Torres I, Salcedo M, López-Hellin J, Sánchez A,
Ramón y Cajal S, et al: HAVCR/KIM-1 activates the IL-6/STAT-3
pathway in clear cell renal cell carcinoma and determines tumor
progression and patient outcome. Cancer Res. 74:1416–1428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ye L, Zhang Q, Cheng Y, Chen X, Wang G,
Shi M, Zhang T, Cao Y, Pan H, Zhang L, et al: Tumor-derived
exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by
promoting TIM-1+ regulatory B cell expansion. J
Immunother Cancer. 6:1452018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gu MM, Gao D, Yao PA, Yu L, Yang XD, Xing
CG, Zhou J, Shang ZF and Li M: p53-inducible gene 3 promotes cell
migration and invasion by activating the FAK/Src pathway in lung
adenocarcinoma. Cancer Sci. 109:3783–3793. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li M, Li S, Liu B, Gu MM, Zou S, Xiao BB,
Yu L, Ding WQ, Zhou PK, Zhou J and Shang ZF: PIG3 promotes NSCLC
cell mitotic progression and is associated with poor prognosis of
NSCLC patients. J Exp Clin Cancer Res. 36:392017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Qin XY, Suzuki H, Honda M, Okada H, Kaneko
S, Inoue I, Ebisui E, Hashimoto K, Carninci P, Kanki K, et al:
Prevention of hepatocellular carcinoma by targeting MYCN-positive
liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci
USA. 115:4969–4974. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Qin XY, Su T, Yu W and Kojima S: Lipid
desaturation-associated endoplasmic reticulum stress regulates MYCN
gene expression in hepatocellular carcinoma cells. Cell Death Dis.
11:662020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lee D, Xu IMJ, Chiu DKC, Leibold J, Tse
APW, Bao MHR, Yuen VWH, Chan CYK, Lai RKH, Chin DWC, et al:
Induction of oxidative stress through inhibition of thioredoxin
reductase 1 is an effective therapeutic approach for hepatocellular
carcinoma. Hepatology. 69:1768–1786. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Muñoz-Gámez JA, López Viota J, Barrientos
A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P,
Delgado Á, Ruiz-Extremera Á and Salmerón J: Synergistic
cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888
and temozolomide in dual-drug targeted magnetic nanoparticles.
Liver Int. 35:1430–1441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wang S, Liu J, Wu H, Jiang A, Zhao K, Yan
K, Wu W, Han H, Zhang Y and Yang W: All-trans retinoic acid (ATRA)
inhibits insufficient radiofrequency ablation (IRFA)-induced
enrichment of tumor-initiating cells in hepatocellular carcinoma.
Chin J Cancer Res. 33:694–707. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Sun J, Liu C, Shi J, Wang N, Jiang D, Mao
F, Gu J, Zhou L, Shen L, Lau WY and Cheng S: A novel chemotherapy
strategy for advanced hepatocellular carcinoma: A multicenter
retrospective study. Chin Med J (Engl). 135:2338–2343. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Augello G, Emma MR, Cusimano A, Azzolina
A, Mongiovì S, Puleio R, Cassata G, Gulino A, Belmonte B,
Gramignoli R, et al: Targeting HSP90 with the small molecule
inhibitor AUY922 (luminespib) as a treatment strategy against
hepatocellular carcinoma. Int J Cancer. 144:2613–2624. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim
TY and Bang YJ: Combination chemotherapy with capecitabine and
cisplatin for patients with metastatic hepatocellular carcinoma.
Ann Oncol. 20:1402–1407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li L, Zhang Y, Zhou Y, Hu H, Hu Y,
Georgiades C, Mao HQ and Selaru FM: Quaternary nanoparticles enable
sustained release of bortezomib for hepatocellular carcinoma.
Hepatology. 76:1660–1672. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW,
Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P
and Stuart K: Phase II study of gemcitabine and oxaliplatin in
combination with bevacizumab in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:1898–1903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
